Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Cotadutide SC vs IV in Healthy Volunteers
NCT05294458Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Primary completion
- Sep 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cotadutide in Nonalcoholic steatohepatitis (NASH), type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), sponsored by AstraZeneca. Primary endpoints: Absolute bioavailability of the high and the low concentration cotadutide SC formulations, Maximum observed concentration and 1 more. Started Mar 2022; status: completed.
02
Drugs
cotadutide
03
Conditions
Nonalcoholic steatohepatitis (NASH)type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05294458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05294458.